A district-wide prescribing study found different benzodiazepine use in insomnia accompanied by anxiety and insomnia accompanied by depression.
What the survey captured
The cross-sectional study covered all 67 primary healthcare facilities in Beijing’s Dongcheng district during 2022. It included 842 patients with insomnia and depressive disorders and 1,014 with insomnia and anxiety disorders. More than nine in ten patients in each group received psychotropic medication.
Benzodiazepines appeared in 55.9% of the depression-comorbidity group and 69.6% of the anxiety-comorbidity group. Z-drug prescribing was approximately 42% in each. These are prescribing proportions within the selected clinical groups, not estimates for all adults with insomnia.
Interpreting guideline concordance
Using their operational definitions, the authors reported guideline-concordant prescribing in 29.9% and 11.5% of the respective groups. A classification based on records can identify a potential care gap, but it does not establish the appropriateness of every individual prescription. Missing clinical indications and treatment histories can affect that judgment.
The setting also matters: district primary care may differ from specialist or tertiary services. The study does not establish medication consumption, sustained treatment benefit, dependence, or impairment in a particular patient. When using these findings in a case, preserve the distinction between a recorded prescribing pattern and an individually assessed treatment decision.
Source paper
Original analysis of the supplied journal article, identified as PMC12926887.
Leave a Reply